-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: October 2011
Public Exits and Virtual Biotechs – Dreams or Reality?
Here at the 10th Annual BIO Investor Forum, investors and CEOs are debating “all the options” for private companies. The first panel of the conference explored the backdoor entrance into public markets as chilly winds continue to blow through the latest IPO window. For the lunch plenary, panelists examined the option to go virtual and make capital efficiency a reality. Reverse Mergers It is no secret that the IPO market for biotechs has been tough. Read More >
Reverse Mergers: A Company is Ready to Go Public, or it’s Not
The latest IPO window has stalled. There have been five IPO withdrawals since June and around 30 since 2005. Global macro events are threatening to completely shut it. Reverse mergers have become an increasingly popular option with eight transactions in the last year. Unfortunately, 47 percent of reverse mergers have decreased in value post-close since 2008. At the 2011 BIO Investor Forum, a panel of experts examined the current financing environment and what private executive Read More >
BioFlorida Conference: Here’s What You Missed
As I mentioned last week, BIO President & CEO James C. Greenwood kicked-off this week’s BioFlorida 14th Annual Conference with a keynote speech. Thanks to @BioFlorida2011 for tweeting some of his speech highlights. If you were not able to make it to Tampa for the conference, fear not, I’ve got you covered. Here’s a rundown of some of the things you missed: It’s All About Efficiency, Innovation and Globalization Goldman Sachs equity analyst Isaac Ro Read More >
Bioenergy Business Outlook Survey Measures Industry Confidence
Biofuels Digests’ Bioenergy Business Outlook Survey, co-sponsored by BIO, is a quarterly indicator of business confidence, financial outlook and growth intentions. The results of the survey provide valuable insight into the mood of leaders in the bioenergy industry. More than a third of respondents each quarter identify themselves as chief executive or owner of their business. Nearly two-thirds of respondents identify themselves as directly involved in bioenergy production, either as producers, investors, business partners or Read More >
BIO Investor Forum Company Snapshot: Protagonist Therapeutics
In our final Investor Forum Company Snapshot, we’ve profiled one of the Discovery Companies who will be presenting at the event. Protagonist Therapeutics shares their take on funding challenges and upcoming priorities, plus interesting facts about their company. Don’t miss their presentation first thing Tuesday morning! Company Snapshot What are the short-term and long-term priorities for your company? Protagonist is a peptide therapeutics based technology platform company. Short term priority: Secure a second collaboration and Read More >
